Financials data is unavailable for this security.
View more
Year on year Shenzhen Neptunus Interlong Bio-technique Co Ltd had net income fall -55.60% from 54.35m to 24.13m despite a 7.92% increase in revenues from 986.69m to 1.06bn. An increase in the cost of goods sold as a percentage of sales from 55.03% to 58.75% was a component in the falling net income despite rising revenues.
| Gross margin | 37.47% |
|---|---|
| Net profit margin | 2.34% |
| Operating margin | 4.49% |
| Return on assets | 1.73% |
|---|---|
| Return on equity | 3.46% |
| Return on investment | 2.56% |
More ▼
Cash flow in CNYView more
In 2023, Shenzhen Neptunus Interlong Bio-technique Co Ltd increased its cash reserves by 28.30%, or 82.11m. Cash Flow from Investing totalled 60.90m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 53.69m in cash from operations while cash used for financing totalled 32.48m.
| Cash flow per share | 0.0002 |
|---|---|
| Price/Cash flow per share | 667.07 |
| Book value per share | 0.6218 |
|---|---|
| Tangible book value per share | 0.5008 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.81 |
|---|---|
| Quick ratio | 2.20 |
| Total debt/total equity | 0.0999 |
|---|---|
| Total debt/total capital | 0.082 |
More ▼
Growth rates in CNY
Year on year, growth in earnings per share excluding extraordinary items dropped -55.60%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
| EPS growth(5 years) | -12.88 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -49.67 |
